Qualification Requirements

Pursuant to Section 28 (c) of RERACA, the Commissioner of Consumer Protection has increased the monthly allotment of medical marijuana for registered medical marijuana patients to 5.0 ounces per month. Patients who have an allotment that has been restricted or expanded by a certifying practitioner will remain unchanged. For logistical reasons, patient’s and caregiver’s who were approved prior to this change will maintain the same 2.5 ounces listed on their registration, however, their monthly allotment will increase to 5.0 ounces at the dispensary facility.

A patient may only register for a medical marijuana certificate if he or she is a Connecticut resident being treated for a debilitating medical condition by a Connecticut-licensed physician, physician assistant or advanced practice registered nurse.

For Adults, Debilitating Medical Conditions Include:

Cancer (Effective 2012)
Glaucoma (Effective 2012)
Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)
Parkinson's Disease (Effective 2012)
Multiple Sclerosis (Effective 2012)
Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)
Epilepsy (Effective 2012)
Cachexia (Effective 2012)
Wasting Syndrome (Effective 2012)
Crohn's Disease (Effective 2012)
Post-Traumatic Stress Disorder (Effective 2012)
Sickle Cell Disease (Effective 2016)*
Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*
Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*
Amyotrophic Lateral Sclerosis (Effective 2016)*
Ulcerative Colitis (Effective 2016)*
Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*
Cerebral Palsy (Effective 2016)
Cystic Fibrosis (Effective 2016)
Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
Terminal Illness Requiring End-Of-Life Care (Effective 2016)
Uncontrolled Intractable Seizure Disorder (Effective 2016)
Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*
Severe Rheumatoid Arthritis (Effective 2018)*
Post Herpetic Neuralgia (Effective 2018)*
Hydrocephalus with Intractable Headache (Effective 2018)*
Intractable Headache Syndromes (Effective 2018)*
Neuropathic Facial Pain (Effective 2018)*
Muscular Dystrophy (Effective 2018)*
Osteogenesis Imperfecta (Effective 2018)*
Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*
Interstitial Cystitis (Effective 2019)*
MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*
Vulvodynia and Vulvar Burning (Effective 2019)*
Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
Tourette Syndrome (Effective 2019)*
Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*
Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
Chronic Pancreatitis (Effective 2021)*
Movement disorders associated with Huntington Disease (Effective 2021)^
Autism Spectrum Disorder (Effective 2024)^
Female Orgasmic Difficulty/Disorder (Effective 2024)^

For Patients Under 18, Debilitating Medical Conditions Include:

Cerebral Palsy (Effective 2016)
Cystic Fibrosis (Effective 2016)
Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)
Severe Epilepsy (Effective 2016)
Terminal Illness Requiring End-Of-Life Care (Effective 2016)
Uncontrolled Intractable Seizure Disorder (Effective 2016)
Muscular Dystrophy (Effective 2018)*
Osteogenesis Imperfecta (Effective 2018)*
Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*
Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*
Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management (Effective 2021)*

* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection. ^ Conditions were approved, pursuant to the Public Act 21-1 the Responsible and Equitable Regulations of Adult-Use Cannabis Act, upon publication on the Department of Consumer Protections website.

Qualifications for a Registration Certificate:

Qualifying patient must be a Connecticut resident.
Qualifying patient cannot be an inmate confined in a correctional institution or facility under the supervision of the Connecticut Department of Corrections.